Conference Coverage

New evidence in melanoma field may be practice changing


 

EXPERT ANALYSIS FROM PMO LIVE

References

Risk and protective factors

New data have implicated medications used to treat erectile dysfunction (ED) as a risk factor for melanoma, raising concern given their widespread use, Dr. Venna said.

A cohort study found that melanoma risk was 84% higher with recent use of sildenafil (Viagra) and 92% higher with ever use (JAMA Intern Med. 2014;174:964-70). But the absolute number of excess cases was fairly small.

A case-control study looking at all types of ED drugs found that receipt of a single prescription was associated with a 32% higher risk of melanoma (JAMA. 2015;313:2449-55). Use increased risk of in situ and stage I melanoma, but not more advanced disease. There was no difference between short- and long-acting agents.

“Prospective studies with clearly defined inclusions and exclusions are needed, with dosing in particular,” Dr. Venna summed up. “There appears to be a modest association, but it certainly is not enough to call for widespread discontinuation. In the patients who are on these drugs, it’s good to document [use] until we have more clarity about the biologic effects of this ultimately.”

A study using dietary surveys and having an average follow-up of more than a decade showed that coffee drinkers had a 20% lower risk of melanoma relative to nondrinkers (J Natl Cancer Inst. 2015 Jan 20;107(2)). But benefit was significant only among the subset drinking at least 4 cups a day.

“It’s premature to advise coffee intake based on this paper, although it does build upon an earlier Norwegian study from the 1990s which showed a similar trend,” Dr. Venna said. “At the end of the day, these data are intriguing, but obviously there are a lot of side effects of trying to consume 4 cups of coffee a day, so further study is certainly warranted.”

Dr. Venna disclosed that he had no relevant conflicts of interest.

Pages

Recommended Reading

Class of 2015: New drugs projected to earn billions and billions
MDedge Family Medicine
Nicotinamide cuts rate of nonmelanoma skin cancer in those at high risk
MDedge Family Medicine
VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?
MDedge Family Medicine
ASCO: Combo therapy results end reign of single-drug therapy in melanoma
MDedge Family Medicine
ASCO: Precision medicine initiatives take wing
MDedge Family Medicine
Annual U.S. incidence of BCC pegged at 2 million
MDedge Family Medicine
Erectile dysfunction meds’ link to melanoma not causal
MDedge Family Medicine
Indoor tanning declines, says CDC
MDedge Family Medicine
Citrus consumption linked to risk of cutaneous malignant melanoma
MDedge Family Medicine
Melanoma twice as likely after CLL/SLL than other types of NHL
MDedge Family Medicine